Division of Neurology, Department of Internal Medicine, Saraburi Hospital, Saraburi, Thailand.
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Stroke Cerebrovasc Dis. 2024 Sep;33(9):107874. doi: 10.1016/j.jstrokecerebrovasdis.2024.107874. Epub 2024 Jul 14.
Systemic inflammation impairs outcomes in acute ischemic stroke (AIS). There is limited knowledge regarding the prognostic value of inflammatory biomarkers derived from complete blood count in predicting in-hospital mortality (IHM) in AIS patients treated with recombinant tissue plasminogen activator (rt-PA). Our study aims to compare the predictive performance of various inflammatory biomarkers for predicting IHM in AIS patients.
This retrospective study included AIS patients treated with rt-PA between January 2015 and July 2022. We identified the following inflammatory biomarkers: white blood cell counts (WBCs), absolute neutrophil count, absolute lymphocyte count, neutrophil to lymphocyte count ratio, platelet to neutrophil ratio, platelet to lymphocyte ratio, red cell distribution width (RDW), RDW to platelet ratio (RPR), and hemoglobin to RDW (HB/RDW) at admission before rt-PA administration. We assessed the predictive value of these biomarkers for IHM by plotting receiver operating characteristic (ROC) curves. The associations between inflammatory biomarkers and IHM were analyzed using multivariable logistic regression (MVLR) analyses.
Of 345 AIS patients, IHM occurred in 65 patients (18.84%). HB/RDW and RDW showed better predictive performance compared to other inflammatory biomarkers. In ROC curve analysis, HB/RDW and RDW had an area under ROC of 0.668. HB/RDW outperformed RDW in terms of the positive likelihood ratio (2.733 vs 1.575), accuracy (0.757 vs 0.585), specificity (0.814 vs 0.560), and positive predictive values (0.388 vs 0.267). In MVLR analysis, RDW, RPR, and HB/RDW remained significantly associated with IHM (per 1-unit increases: odds ratios (ORs) = 1.450, 95% CI: [1.178-1.784]; per 1-unit increases: ORs = 1.329, 95% CI [1.103-1.602]; and per 0.1-unit decreases: ORs = 1.412, 95% CI [1.089-1.831], respectively).
The association between HB/RDW and IHM in AIS patients treated with rt-PA was significant. HB/RDW exhibited superior predictive performance compared to other inflammatory biomarkers in predicting IHM.
全身炎症会影响急性缺血性脑卒中(AIS)的预后。目前对于接受重组组织型纤溶酶原激活剂(rt-PA)治疗的 AIS 患者,来自全血细胞计数的炎症生物标志物预测院内死亡率(IHM)的预后价值知之甚少。我们的研究旨在比较各种炎症生物标志物预测 AIS 患者 IHM 的预测性能。
本回顾性研究纳入了 2015 年 1 月至 2022 年 7 月期间接受 rt-PA 治疗的 AIS 患者。我们确定了以下炎症生物标志物:白细胞计数(WBCs)、绝对中性粒细胞计数、绝对淋巴细胞计数、中性粒细胞与淋巴细胞比值、血小板与中性粒细胞比值、血小板与淋巴细胞比值、红细胞分布宽度(RDW)、RDW 与血小板比值(RPR)和血红蛋白与 RDW(HB/RDW)。我们通过绘制受试者工作特征(ROC)曲线评估这些生物标志物对 IHM 的预测价值。使用多变量逻辑回归(MVLR)分析评估炎症生物标志物与 IHM 之间的关联。
在 345 名 AIS 患者中,65 名患者(18.84%)发生 IHM。HB/RDW 和 RDW 的预测性能优于其他炎症生物标志物。在 ROC 曲线分析中,HB/RDW 和 RDW 的 ROC 曲线下面积分别为 0.668。HB/RDW 的阳性似然比(2.733 比 1.575)、准确性(0.757 比 0.585)、特异性(0.814 比 0.560)和阳性预测值(0.388 比 0.267)均优于 RDW。在 MVLR 分析中,RDW、RPR 和 HB/RDW 与 IHM 仍显著相关(每增加 1 个单位:比值比(ORs)=1.450,95%CI:[1.178-1.784];每增加 1 个单位:ORs=1.329,95%CI [1.103-1.602];每减少 0.1 个单位:ORs=1.412,95%CI [1.089-1.831])。
接受 rt-PA 治疗的 AIS 患者的 HB/RDW 与 IHM 之间存在显著关联。HB/RDW 在预测 IHM 方面优于其他炎症生物标志物。